Dr. W. Shannon McCool, D.Ph.
With its headquarters in Tennessee, RxBio is a biotechnology company that produces Rx100, a product which protects against lethal, whole-body radiation and gastrointestinal tract damage as a result of radiation, chemotherapy, and various toxins. Rx100 works by boosting natural mechanisms that promote and sustain cell survival after injury in almost every cell type.
RxBio’s Radioprotectant / Radiomitigator Technology is being channeled into two development pathways: gut protection: protection of the gut from a variety of sources (radiation, chemotherapy, toxins, etc.) and whole-body protection: “We anticipate formulation in a pre-filled, field-rugged, injector for subcutaneous self-, partner-, or medical- administration within 24 hours of a radiation exposure. Doses can formulated and tailored for a wide range of patient types (infants to geriatrics).”
Chair and CEO of RxBio, Dr. McCool has spent over 40 years involved in the development and commercialization of pharmaceutical products. He has worked for Eli Lilly and Company and has served as head of strategic planning, corporate licensing, and business development for the U.S. operations of Beechman Laboratories (now GlaxoSmithKline.) For more, go to http://www.rxbio.com